title: Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients.
abstract: Topiramate is an approved and effective drug in migraine prophylaxis. Paresthesia is the most commonly reported side effect. The primary objective of this study was to compare the frequency of topiramate-induced paresthesia in migraine headache to epileptic patients. Patients with migraine without aura and epilepsy were enrolled in this observational study. All cases were interviewed by telephone about their history of paresthesia. Confounding factors were controlled through logistic regression. The odds ratio of developing topiramate-induced paresthesia in migraine compared to epilepsy patients was 3.4. Three factors were independent contributors to developing topiramate-induced paresthesia: female sex (odds ratio 2.1), topiramate dosage (odds ratio 0.3) and duration of therapy. Our findings indicate an independent association between migraine and development of paresthesia. Migraineurs were more likely than epileptic patients to report paresthesia as topiramate adverse effects. Female sex, treatment duration and topiramate dosage contribute significantly to subsequent development of paresthesia.
authors.affiliation: Department of Neurology, Neurology Research Centre, Kerman University of Medical Sciences, Kerman, Iran.
authors.forename: Behnaz
authors.initials: B
authors.lastname: Sedighi
authors.affiliation: Department of Neurology, Neurology Research Centre, Kerman University of Medical Sciences, Kerman, Iran. kshafiee@gmail.com.
authors.forename: Kaveh
authors.initials: K
authors.lastname: Shafiei
authors.affiliation: Department of Neurology, Neurology Research Centre, Kerman University of Medical Sciences, Kerman, Iran.
authors.forename: Iman
authors.initials: I
authors.lastname: Azizpour
mesh_terms: D000293:Adolescent; D000328:Adult; D002491:Central Nervous System Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004827:Epilepsy / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy / Q000453:epidemiology*; D016017:Odds Ratio; D010292:Paresthesia / Q000139:chemically induced* / Q000453:epidemiology*; D000077236:Topiramate; D055815:Young Adult
chemical_list: D002491:Central Nervous System Agents; D000077236:Topiramate; D005632:Fructose
keywords: Migraine; Paresthesia; Topiramate
references.citation: J Cent Nerv Syst Dis. 2011 Jun 23;3:155-68
references.pmid: 23861645
references.citation: Panminerva Med. 2013 Sep;55(3):303-7
references.pmid: 24088805
references.citation: Int J Clin Pract. 2005 Aug;59(8):961-8
references.pmid: 16033621
references.citation: Headache. 2007 Feb;47(2):170-80
references.pmid: 17300356
references.citation: Headache. 2005 Apr;45 Suppl 1:S66-73
references.pmid: 15833092
references.citation: Health Qual Life Outcomes. 2007 Oct 04;5:56
references.pmid: 17916258
references.citation: J Young Pharm. 2013 Mar;5(1):30-1
references.pmid: 24023450
references.citation: Eur J Neurol. 2007 Jun;14(6):654-8
references.pmid: 17539944
references.citation: Clin Ther. 2009 Mar;31(3):542-59
references.pmid: 19393844
references.citation: Eur J Neurol. 2007 Aug;14(8):900-6
references.pmid: 17662012
references.citation: Clin Pharmacol Ther. 2009 Mar;85(3):283-8
references.pmid: 18987621
references.citation: Headache. 2012 Jun;52(6):930-45
references.pmid: 22671714
references.citation: Headache. 2005 Apr;45 Suppl 1:S57-65
references.pmid: 15833091
references.citation: Headache. 2006 Oct;46(9):1424-30
references.pmid: 17040339
references.citation: Ann Neurol. 2000 May;47(5):614-24
references.pmid: 10805332
references.citation: J Am Osteopath Assoc. 2007 Jul;107(7):251-8
references.pmid: 17682112
references.citation: CNS Spectr. 2003 Jun;8(6):428-32
references.pmid: 12858132
references.citation: Epilepsy Res. 1997 Oct;28(3):167-79
references.pmid: 9332882
references.citation: JAMA. 2004 Feb 25;291(8):965-73
references.pmid: 14982912
references.citation: Clin Ther. 2006 Jul;28(7):1002-11
references.pmid: 16990078
references.citation: Neuropsychiatr Dis Treat. 2010 Feb 03;6:17-28
references.pmid: 20169042
references.citation: MedGenMed. 2004 Jul 14;6(3):48
references.pmid: 15520672
references.citation: Clin Ther. 2005 Feb;27(2):154-65
references.pmid: 15811478
references.citation: Neurology. 2007 Jan 30;68(5):343-9
references.pmid: 17261680
references.citation: Epilepsy Res. 2005 Feb;63(2-3):103-12
references.pmid: 15715969
references.citation: Pain Med. 2008 Mar;9(2):175-85
references.pmid: 18298700
references.citation: Headache. 2005 Sep;45(8):1023-30
references.pmid: 16109116
references.citation: Br J Pharmacol. 2004 Jul;142(5):831-42
references.pmid: 15197104
references.citation: Headache. 2006 Nov;46 Suppl 4:S182-91
references.pmid: 17078850
references.citation: Neurosciences (Riyadh). 2006 Apr;11(2):84-7
references.pmid: 22266554